RBAK-RBAKDN

Across TCGA pan-cancer cohorts, RBAK-RBAKDN Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RBAK-RBAKDN data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBAK-RBAKDN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBAK-RBAKDN expression acts as an unfavorable survival marker.

HNSC and PRAD are the cancer types where RBAK-RBAKDN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.078	0.710	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RBAK-RBAKDN–HNSC (DFS)

Open the HNSC breakdown →